urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2025-13-5-80-85urovest-1133Research ArticleОБМЕН ПРАКТИЧЕСКИМ ОПЫТОМEXCHANGE OF PRACTICAL EXPERIENCEВлияние интравезикальной протрузии простаты на результаты лечения пациентов с гиперплазией предстательной железыThe impact of intravesical prostate protrusion on the treatment outcomes in patients with benign prostatic hyperplasiahttps://orcid.org/0000-0002-3854-7429ШахраиниР.ShahrainiR.

Рамин Шахраини — ассистент-профессор

Сабзевар

Ramin Shahraini — Assist. Prof.

Sabzevar

raminasghar1376@gmail.comАгхабартиР.AghaBaratiR.

Рейхане Агхабарти

Сабзевар

Reyhaneh AghaBarati

Sabzevar

Reyhaneaghabarati@yahoo.comhttps://orcid.org/0000-0002-5416-2780ТаббариеиЯ.TabarraieYa.

Ясер Таббариеи — доктор философии, ассистент-профессор

Сабзевар

Yaser Tabarraie — Ph.D., Assist. Prof. 

Sabzevar

yasertabarraie@yahoo.comhttps://orcid.org/0000-0003-0803-7679ДжаламбаданиЗ.JalambadaniZ.

Зейнаб Джаламбадани — доктор философии, ассистент-профессор

Сабзевар

Zeinab Jalambadani — Ph.D., Assist. Prof. 

Sabzevar

jalambadaniz@gmail.comhttps://orcid.org/0000-0003-1816-7645МехрманешМ.MehrmaneshM.

Малихе Мехрманеш — магистр акушерства

Тегеран

Maliheh Mehrmanesh — M.Sc. in Midwifery

Tehran

Mehrmanesh@gmail.comСабзеварский университет медицинских наукИранSabzevar University of Medical SciencesIslamic Republic of IranИсламский университет АзадИранIslamic Azad University (IAU)Islamic Republic of Iran2025221220251358085Copyright © Шахраини Р., Агхабарти Р., Таббариеи Я., Джаламбадани З., Мехрманеш М., 20252025Шахраини Р., Агхабарти Р., Таббариеи Я., Джаламбадани З., Мехрманеш М.Shahraini R., AghaBarati R., Tabarraie Y., Jalambadani Z., Mehrmanesh M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/1133Введение

Введение. Гиперплазия предстательной железы (ГПЖ) является самой частой причиной инфравезикальной обструкции у мужчин старше 50 лет с симптомами нижних мочевых путей.

Цель исследования

Цель исследования. Оценить влияние интравезикальной протрузии простаты (intravesical prostatic protrusion, IPP), по данным сонографии, на эффективность медикаментозной терапии у пациентов с ГПЖ.

Материалы и методы

Материалы и методы. Исследование носило описательно-аналитический квази-экспериментальный характер. В зависимости от наличия или отсутствия IPP, по данным ультразвукового исследования, 80 пациентов были разделены на две группы. До терапии и через один месяц после неё альфа-адреноблокатором у пациентов измеряли остаточный объём мочи (PVR) и суммарный балл IPSS, после чего сравнивали динамику этих показателей между группами.

Результаты

Результаты. Средний возраст пациентов обеих групп составил 66,08 ± 10,8 года. После лечения альфа-адреноблокаторами средний PVR у пациентов с IPP составил 6,82 ± 5,6 мл, а у пациентов без IPP — 25,37 ± 15,57 мл (p < 0,001). После терапии средний балл IPSS у пациентов с IPP составил 6,78 ± 9,52, а у пациентов без IPP — 12,55 ± 6,99 (p = 0,388).

Заключение

Заключение. Полученные данные свидетельствуют о том, что эффект терапии альфа-адреноблокаторами у пациентов с IPP был более выраженным, чем у пациентов без IPP, что подчёркивает целесообразность применения альфа-адреноблокаторов у больных ДГПЖ с наличием интравезикальной протрузии простаты.

Introduction

Introduction. Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over 50 years old who have lower urinary tract symptoms.

Objective

Objective. To investigate the impact of intravesical prostate protrusion (IPP) during sonography concerning the response to medical treatment in patients with BPH.

Materials & methods

Materials & methods. This study is a descriptive-analytical quasi-experimental. The individuals (80 patients) were divided into two groups based on the presence or absence of IPP as seen in ultrasound. Before and after one month of treatment with the alpha-blocker, PVR and IPSS were measured in the patients, and the improvement trends in the two groups were compared.

Results

Results. The mean age of patients in both groups was 66.08 ± 10.8 years. After treatment with alpha-blockers, the mean PVR in IPP-patients was 6.82 ± 5.6 ml, and in no-IPP-patients it was 25.37 ± 15.57 ml (P > 0.001). After treatment with alpha-blockers, the mean score in IPP-patients was 6.78 ± 9.52, and in no-IPP-patients it was 12.55± 6.99 (P = 0.388).

Conclusion

Conclusion. The results indicate that the effect of the alpha-blocker medication on patients with IPP was greater than on those without IPP, highlighting the positive impact of using alpha-blockers in patients with BPH who have IPP.

предстательная железамочевой пузырьобъём остаточной мочиальфаадреноблокаторыprostaticbladderresidual urine volumealpha-blockersReferencesKalkanli A, Tandogdu Z, Aydin M, Karaca AS, Hazar AI, Balci MB, Aydin M, Nuhoglu B. Intravesical Prostatic Protrusion: A Potential Marker of Alpha-blocker Treatment Success in Patients With Benign Prostatic Enlargement. Urology. 2016;88:161-5. DOI: 10.1016/j.urology.2015.11.029Kalkanli A, Tandogdu Z, Aydin M, Karaca AS, Hazar AI, Balci MB, Aydin M, Nuhoglu B. Intravesical Prostatic Protrusion: A Potential Marker of Alpha-blocker Treatment Success in Patients With Benign Prostatic Enlargement. Urology. 2016;88:161-5. DOI: 10.1016/j.urology.2015.11.029Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, Wilt TJ. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-19. DOI: 10.1097/JU.0000000000003698Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, Wilt TJ. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-19. DOI: 10.1097/JU.0000000000003698Wei H, Zhu C, Huang Q, Yang J, Li YT, Zhang YG, Li BH, Zi H. Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035. BMC Urol. 2025;25(1):34. DOI: 10.1186/s12894-025-01715-9Wei H, Zhu C, Huang Q, Yang J, Li YT, Zhang YG, Li BH, Zi H. Global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021 and projection to 2035. BMC Urol. 2025;25(1):34. DOI: 10.1186/s12894-025-01715-9Wolfe RC, Portell J, Maamari JA. Pharmacologic Management of Postoperative Urinary Retention. J Perianesth Nurs. 2023;38(4):667-670. DOI: 10.1016/j.jopan.2023.05.006Wolfe RC, Portell J, Maamari JA. Pharmacologic Management of Postoperative Urinary Retention. J Perianesth Nurs. 2023;38(4):667-670. DOI: 10.1016/j.jopan.2023.05.006Britto-Júnior J, Guimarães RAB, Oliveira DL, Lima AT, Quirino Junior G, de Oliveira Stocco GA, Salgado Uramoto EH, Fregonesi A, Antunes E, De Nucci G. Alpha1-adrenergic blockers selectively antagonize the contractions induced by 6-nitrodopamine in the human vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(5):3227-3238. DOI: 10.1007/s00210-023-02805-xBritto-Júnior J, Guimarães RAB, Oliveira DL, Lima AT, Quirino Junior G, de Oliveira Stocco GA, Salgado Uramoto EH, Fregonesi A, Antunes E, De Nucci G. Alpha1-adrenergic blockers selectively antagonize the contractions induced by 6-nitrodopamine in the human vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(5):3227-3238. DOI: 10.1007/s00210-023-02805-xSciacqua LV, Vanzulli A, Di Meo R, Pellegrino G, Lavorato R, Vitale G, Carrafiello G. Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH). Technol Cancer Res Treat. 2023;22:15330338231155000. DOI: 10.1177/15330338231155000Sciacqua LV, Vanzulli A, Di Meo R, Pellegrino G, Lavorato R, Vitale G, Carrafiello G. Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH). Technol Cancer Res Treat. 2023;22:15330338231155000. DOI: 10.1177/15330338231155000Chughtai B, Rojanasarot S, Neeser K, Gultyaev D, Fu S, Bhattacharyya SK, El-Arabi AM, Cutone BJ, McVary KT. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. PLoS One. 2022;17(4):e0266824. DOI: 10.1371/journal.pone.0266824Chughtai B, Rojanasarot S, Neeser K, Gultyaev D, Fu S, Bhattacharyya SK, El-Arabi AM, Cutone BJ, McVary KT. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. PLoS One. 2022;17(4):e0266824. DOI: 10.1371/journal.pone.0266824Eze BU, Amu OC, Edeh JA. A Review of Intravesical Prostatic Protrusion in the Evaluation and Treatment of Benign Prostatic Enlargement. European Journal of Medical and Health Sciences. 2021;3(1):13-17.Eze BU, Amu OC, Edeh JA. A Review of Intravesical Prostatic Protrusion in the Evaluation and Treatment of Benign Prostatic Enlargement. European Journal of Medical and Health Sciences. 2021;3(1):13-17.Suastari NMP, Mahayani NMW, Dinata DKAHP. Correlation between Prostate Volume and Intravesical Prostate Protrusion to Bladder Detrusor Muscle Thickness in Patients with Benign Prostate Enlargement by Transabdominal Ultrasound Examination in Banjar Jagatamu, Meliling, Kerambitan, Tabanan 2024. Al Makki Health Informatics Journal. 2025;3(1):37-43.Suastari NMP, Mahayani NMW, Dinata DKAHP. Correlation between Prostate Volume and Intravesical Prostate Protrusion to Bladder Detrusor Muscle Thickness in Patients with Benign Prostate Enlargement by Transabdominal Ultrasound Examination in Banjar Jagatamu, Meliling, Kerambitan, Tabanan 2024. Al Makki Health Informatics Journal. 2025;3(1):37-43.Chen X, Yang S, He Z, Chen Z, Tang X, Lin Y, Huang Y, Hou J, Wei X. Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021. Sci Rep. 2025;15(1):5644. DOI: 10.1038/s41598-025-90229-3Chen X, Yang S, He Z, Chen Z, Tang X, Lin Y, Huang Y, Hou J, Wei X. Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021. Sci Rep. 2025;15(1):5644. DOI: 10.1038/s41598-025-90229-3Raffo M, Capogrosso P, Pozzi E, Belladelli F, Corsini C, Bertini A, Negri F, Candela L, Larcher A, Matloob R, d’Arma A, Montorsi F, Salonia A. Clinical predictors of bladder outlet obstruction in men consulting for routine urological screening. Int Urol Nephrol. 2025;57(8):2513-2518. DOI: 10.1007/s11255-025-04432-2Raffo M, Capogrosso P, Pozzi E, Belladelli F, Corsini C, Bertini A, Negri F, Candela L, Larcher A, Matloob R, d’Arma A, Montorsi F, Salonia A. Clinical predictors of bladder outlet obstruction in men consulting for routine urological screening. Int Urol Nephrol. 2025;57(8):2513-2518. DOI: 10.1007/s11255-025-04432-2Creta M, Baboudjian M, Sakalis V, Bhatt N, Nunzio C, Gacci M, Herrmann TRW, Karavitakis M, Malde S, Moris L, Netsch C, Rieken M, Schouten N, Tutolo M, Yuan Y, Hashim H, Cornu JN. Management of Primary Bladder Neck Obstruction and Dysfunctional Voiding in Young Men: A Systematic Review and Meta-analysis. Eur Urol Focus. 2025;11(3):496-507. DOI: 10.1016/j.euf.2025.01.011Creta M, Baboudjian M, Sakalis V, Bhatt N, Nunzio C, Gacci M, Herrmann TRW, Karavitakis M, Malde S, Moris L, Netsch C, Rieken M, Schouten N, Tutolo M, Yuan Y, Hashim H, Cornu JN. Management of Primary Bladder Neck Obstruction and Dysfunctional Voiding in Young Men: A Systematic Review and Meta-analysis. Eur Urol Focus. 2025;11(3):496-507. DOI: 10.1016/j.euf.2025.01.011Cumpanas AA, Botoca M, Minciu R, Bucuras V. Intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin. Urology. 2013;81(4):859-863. DOI: 10.1016/j.urology.2012.12.007Cumpanas AA, Botoca M, Minciu R, Bucuras V. Intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin. Urology. 2013;81(4):859-863. DOI: 10.1016/j.urology.2012.12.007Yoshida T, Kinoshita H, Yoshida K, Mishima T, Taniguchi H, Yanishi M, Komai Y, Yasuda K, Sugi M, Matsuda T. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride. Urology. 2016;91:154-157. DOI: 10.1016/j.urology.2016.01.009Yoshida T, Kinoshita H, Yoshida K, Mishima T, Taniguchi H, Yanishi M, Komai Y, Yasuda K, Sugi M, Matsuda T. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride. Urology. 2016;91:154-157. DOI: 10.1016/j.urology.2016.01.009Lee HJ, Lee A, Huang HH, Sundaram P, Foo KT. Patients with small prostates and low-grade intravesical prostatic protrusion – A urodynamic evaluation. Asian J Urol. 2017;4(4):247-252. DOI: 10.1016/j.ajur.2017.03.003Lee HJ, Lee A, Huang HH, Sundaram P, Foo KT. Patients with small prostates and low-grade intravesical prostatic protrusion – A urodynamic evaluation. Asian J Urol. 2017;4(4):247-252. DOI: 10.1016/j.ajur.2017.03.003

The authors declare that there are no conflicts of interest present.